20:49 , Dec 19, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Cognitive dysfunction Patient sample and mouse studies suggest inhibiting HMGB1 or reactive oxygen species (ROS) could help treat necrotizing enterocolitis-associated cognitive impairments. In infants with necrotizing enterocolitis, serum levels of HMGB1 and brain levels...
20:11 , Nov 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Epilepsy; seizures Rat studies suggest glycyrrhizin could help treat status epilepticus. In a rat model of lithium-pilocarpine-induced status epilepticus, glycyrrhizin -- which inhibits HMGB1 -- decreased blood-brain barrier (BBB) disruption and hippocampal neuronal damage...
19:51 , Jul 28, 2017 |  BC Week In Review  |  Company News

Feinstein grants Applied Immunotherapeutics rights to HMGB1 candidates

The Feinstein Institute for Medical Research (Manhasset, N.Y.) granted Applied Immunotherapeutics Inc. (Morris, Conn.) exclusive, worldwide rights to three preclinical candidates. Applied Immunotherapeutics gained rights to 2G7 , a mAb against high mobility group box...